Loading...
01/11 11:27
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance with a 12.4% revenue increase and a 500% rise in adjusted EBITDA, which is very positive. The share repurchase program expansion also supports stock price appreciation. However, some concerns exist regarding de novo losses and operational challenges. The Q&A section indicates optimism about enrollment trends and operational efficiencies. Overall, the positive financial results and strategic initiatives outweigh the challenges, leading to a positive sentiment.
Total Revenues $205.1 million, an increase of approximately 12% from $182.5 million in Q1 FY 2024, driven by an increase in member months and capitation rates.
Adjusted EBITDA $6.5 million, an increase of approximately 500% from $1.3 million in Q1 FY 2024, reflecting improved operational efficiency and revenue growth.
Center Level Contribution Margin $34.5 million, compared to $27.9 million in Q1 FY 2024, with a margin percentage increase from 15.3% to 16.8%.
Census Approximately 7,210 participants, representing a year-over-year growth of approximately 10% compared to Q1 FY 2024.
External Provider Costs $107.2 million, an increase of approximately 7.9% compared to Q1 FY 2024, primarily driven by an increase in member months.
Cost of Care (excluding depreciation and amortization) $63.4 million, an increase of 14.7% compared to Q1 FY 2024, driven by increased member months and higher salaries, wages, and benefits.
Net Loss $5.7 million, improved from a net loss of $11 million in Q1 FY 2024.
Net Loss per Share $0.04, on both a basic and diluted basis.
Cash Flow from Operations Negative cash flow of $7.5 million for the quarter.
Cash and Cash Equivalents $39 million, plus $46.7 million in short-term investments.
Total Debt $81.3 million, representing debt under senior secured term loan, convertible term loan, and finance leases.
Sales and Marketing Expenses Approximately $6.5 million, an increase of 20.7% compared to Q1 FY 2024, primarily due to increased headcount.
Corporate, General and Administrative Expenses $27.5 million, a decrease of 4.9% compared to Q1 FY 2024, due to reductions in insurance and consulting expenses.
De Novo Losses $4.1 million, primarily related to new centers, compared to $1.6 million in Q1 FY 2024.
Census Growth: Census increased to approximately 7,210, representing a 10% year-over-year growth compared to the first quarter of fiscal 2024.
Enrollment Trends: Enrollment processing delays are being addressed, with signs of improvement in Colorado and California. Florida markets are also contributing positively despite challenges.
Adjusted EBITDA: Adjusted EBITDA increased by approximately 500% from $1.3 million in Q1 FY 2024 to $6.5 million in Q1 FY 2025.
Employee Engagement Score: Employee Engagement Score reached 79%, indicating strong employee satisfaction.
Net Promoter Score: Net Promoter Score reached a new high of 56, indicating improved participant satisfaction.
Cost Management: External provider cost PMPM increased by 1.6%, while inpatient admissions decreased to 5.1%.
Leadership Change: Michael Scarbrough appointed as President and COO, bringing extensive experience in government healthcare programs.
Operational Initiatives: Continued focus on clinical and operational value initiatives to manage medical costs and improve margins.
Regulatory Issues: The company is currently facing open state audit processes in Sacramento and San Bernardino, which may impact the timeline for opening new locations in Bakersfield and Downey.
Enrollment Delays: Enrollment processing delays due to bottlenecks in obtaining level of care assessments are affecting growth, although there are signs of improvement in processing times.
Competitive Pressures: The company anticipates seasonal variations in enrollment patterns during the Medicare annual enrollment period, which may affect competitive positioning.
Supply Chain Challenges: The company is experiencing increased costs in pharmacy and assisted living services, which are growing proportionally with census.
Economic Factors: The broader financial pressures affecting the Medicare Advantage sector may impact the company's competitive position.
Operational Risks: The company is managing utilization volatility, particularly in inpatient admissions and short-stay nursing utilization, which requires constant vigilance.
De Novo Losses: The company expects de novo losses for fiscal 2025 to be in the range of $18 million to $20 million, indicating ongoing challenges in ramping up new centers.
Total Revenues Q1 2025: Total revenues of $205.1 million, a 12% increase from $182.5 million in Q1 2024.
Adjusted EBITDA Q1 2025: Adjusted EBITDA of $6.5 million, a 500% increase from $1.3 million in Q1 2024.
Census Growth: Census increased to approximately 7,210, representing a 10% year-over-year growth.
Employee Engagement Score: Employee Engagement Score reached 79%, indicating strong employee satisfaction.
Net Promoter Score: Net Promoter Score reached a new high of 56, indicating improved participant satisfaction.
Strategic Leadership Changes: Michael Scarbrough appointed as new President and COO, bringing extensive experience in government healthcare programs.
Clinical and Operational Value Initiatives: Progress in clinical and operational value initiatives aimed at improving margins and managing costs.
Fiscal 2025 Revenue Guidance: Projected total revenue in the range of $815 million to $865 million.
Fiscal 2025 Adjusted EBITDA Guidance: Projected adjusted EBITDA in the range of $24 million to $31 million.
Census Guidance: Expected ending census for fiscal year 2025 to be between 7,300 and 7,750 participants.
De Novo Losses Guidance: Anticipated de novo losses for fiscal 2025 will be in the $18 million to $20 million range.
Share Repurchase Program: During the first quarter, the company repurchased approximately 801,300 shares of its common stock for an aggregate of approximately $4.8 million under the company's share repurchase plan. In September, the board increased the size of the share repurchase program by an additional $2.5 million.
The earnings call presented strong financial results with a 15% revenue increase and a significant improvement in adjusted EBITDA. Despite challenges like higher costs and regulatory risks, the company achieved its first positive net income since 2021. The Q&A highlighted confidence in guidance and effective cost management, though some responses lacked clarity. Overall, the optimistic financial performance and strategic focus on operational efficiency suggest a positive stock price movement in the near term.
Despite strong census growth and improved EBITDA margins, the increase in net loss and higher operational costs, along with uncertainties around B-28 and Medicaid redeterminations, create a mixed outlook. The positive aspects, such as partnerships and automation efforts, are counterbalanced by these challenges, leading to a neutral sentiment.
The earnings call presents a mixed picture: a 10.6% revenue increase and positive guidance are offset by higher losses, negative cash flow, and asset impairments. Share repurchases and margin improvements are positive, but uncertainties in Medicare funding and unclear management responses introduce risk. The lack of significant new partnerships or guidance changes tempers potential positive sentiment, suggesting a neutral stock price movement.
The earnings call highlights strong financial performance with a 12.4% revenue increase and a 500% rise in adjusted EBITDA, which is very positive. The share repurchase program expansion also supports stock price appreciation. However, some concerns exist regarding de novo losses and operational challenges. The Q&A section indicates optimism about enrollment trends and operational efficiencies. Overall, the positive financial results and strategic initiatives outweigh the challenges, leading to a positive sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
